. Author manuscript; available in PMC: 2020 Dec 29.

Published in final edited form as: Target Oncol. 2019 Oct;14(5):613–618. doi: 10.1007/s11523-019-00661-5

Table 4.

Best response and duration of therapy by dose and tumor type

Dose (mg/m²)	No. of patients	Primary tumor site (n)	Duration of therapy (mo)	Best response	Reason for discontinuation
120	1	CRC	1.2	PD	PD
200	1	CRC	1.1	PD	PD
330	1	HCC	2.6	SD	PD
500	1	CRC	5.4	SD	PD
750	1	Colon neuroendocrine	4.3	SD	Toxicity (LFTs)
1050	1	CRC	0.8	PD	PD
1470	1	CRC	1.4	PD	PD
2060	6	CRC (4)	Median: 1.3	SD (1)	PD (5)
		Gallbladder (1)	Range: 0.8–6.7	PD (5)	Sponsor decision (1)
		Unspecified (1)

CRC colorectal cancer, HCC hepatocellular carcinoma, LFTs liver function tests, PD progressive disease, SD stable disease